All In MedTech

FDA Clearance Tracker · P170024

Surpass Streamline Flow Diverter

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jul 13, 2018 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jul 13, 2018

Approved

Time to decision

347 days

Received Jul 31, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P170024
Device name
Surpass Streamline Flow Diverter
Applicant location
Fremont, CA
Received
Jul 31, 2017
Decided
Jul 13, 2018
Decision
Approved
Supplements
26 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OUT

FDA's approval statement

As written in FDA's record.

Approval for The Surpass Streamline Flow Diverter. The Surpass Streamline Flow Diverter is indicated for use in the endovascular treatment of patients (18 years of age and older) with unruptured large or giant saccular wide-neck (neck width >= 4 mm or dome-to-neck ratio < 2) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter >= 2.5 mm and <= 5.3 mm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code OUT. The earliest in FDA's data is P100018, decided Apr 6, 2011.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Stryker Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.